The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
Identifieur interne : 000169 ( PubMed/Corpus ); précédent : 000168; suivant : 000170The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
Auteurs : Aleksandar. Risti ; Nikola Vojvodi ; Slavko Jankovi ; Aleksandra Sindeli ; Dragoslav SokiSource :
- Epilepsia [ 0013-9580 ] ; 2006.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Anticonvulsants (adverse effects), Anticonvulsants (therapeutic use), Cognition Disorders (chemically induced), Cognition Disorders (epidemiology), Drug Administration Schedule, Drug Therapy, Combination, Epilepsy (classification), Epilepsy (diagnosis), Epilepsy (drug therapy), Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (epidemiology), Prevalence, Severity of Illness Index, Treatment Outcome, Valproic Acid (adverse effects), Valproic Acid (therapeutic use).
- MESH :
- chemical , adverse effects : Anticonvulsants, Valproic Acid.
- chemical , therapeutic use : Anticonvulsants, Valproic Acid.
- chemically induced : Cognition Disorders, Parkinson Disease, Secondary.
- classification : Epilepsy.
- diagnosis : Epilepsy.
- drug therapy : Epilepsy.
- epidemiology : Cognition Disorders, Parkinson Disease, Secondary.
- Adolescent, Adult, Aged, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prevalence, Severity of Illness Index, Treatment Outcome.
Abstract
We report the frequency of parkinsonism and cognitive decline (P/CD) in patients treated with valproate (VPA) after 1 year of treatment and at least 1 year of follow-up.
DOI: 10.1111/j.1528-1167.2006.00711.x
PubMed: 17201721
Links to Exploration step
pubmed:17201721Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.</title><author><name sortKey="Risti, Aleksandar J" sort="Risti, Aleksandar J" uniqKey="Risti A" first="Aleksandar" last="Risti">Aleksandar. Risti</name><affiliation><nlm:affiliation>Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="Vojvodi, Nikola" sort="Vojvodi, Nikola" uniqKey="Vojvodi N" first="Nikola" last="Vojvodi">Nikola Vojvodi</name></author><author><name sortKey="Jankovi, Slavko" sort="Jankovi, Slavko" uniqKey="Jankovi S" first="Slavko" last="Jankovi">Slavko Jankovi</name></author><author><name sortKey="Sindeli, Aleksandra" sort="Sindeli, Aleksandra" uniqKey="Sindeli A" first="Aleksandra" last="Sindeli">Aleksandra Sindeli</name></author><author><name sortKey="Soki, Dragoslav" sort="Soki, Dragoslav" uniqKey="Soki D" first="Dragoslav" last="Soki">Dragoslav Soki</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1111/j.1528-1167.2006.00711.x</idno><idno type="RBID">pubmed:17201721</idno><idno type="pmid">17201721</idno><idno type="wicri:Area/PubMed/Corpus">000169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.</title><author><name sortKey="Risti, Aleksandar J" sort="Risti, Aleksandar J" uniqKey="Risti A" first="Aleksandar" last="Risti">Aleksandar. Risti</name><affiliation><nlm:affiliation>Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="Vojvodi, Nikola" sort="Vojvodi, Nikola" uniqKey="Vojvodi N" first="Nikola" last="Vojvodi">Nikola Vojvodi</name></author><author><name sortKey="Jankovi, Slavko" sort="Jankovi, Slavko" uniqKey="Jankovi S" first="Slavko" last="Jankovi">Slavko Jankovi</name></author><author><name sortKey="Sindeli, Aleksandra" sort="Sindeli, Aleksandra" uniqKey="Sindeli A" first="Aleksandra" last="Sindeli">Aleksandra Sindeli</name></author><author><name sortKey="Soki, Dragoslav" sort="Soki, Dragoslav" uniqKey="Soki D" first="Dragoslav" last="Soki">Dragoslav Soki</name></author></analytic><series><title level="j">Epilepsia</title><idno type="ISSN">0013-9580</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Anticonvulsants (adverse effects)</term><term>Anticonvulsants (therapeutic use)</term><term>Cognition Disorders (chemically induced)</term><term>Cognition Disorders (epidemiology)</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Epilepsy (classification)</term><term>Epilepsy (diagnosis)</term><term>Epilepsy (drug therapy)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (epidemiology)</term><term>Prevalence</term><term>Severity of Illness Index</term><term>Treatment Outcome</term><term>Valproic Acid (adverse effects)</term><term>Valproic Acid (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term><term>Valproic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Valproic Acid</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Epilepsy</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Epilepsy</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epilepsy</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report the frequency of parkinsonism and cognitive decline (P/CD) in patients treated with valproate (VPA) after 1 year of treatment and at least 1 year of follow-up.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17201721</PMID><DateCreated><Year>2007</Year><Month>01</Month><Day>04</Day></DateCreated><DateCompleted><Year>2007</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-9580</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.</ArticleTitle><Pagination><MedlinePgn>2183-5</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We report the frequency of parkinsonism and cognitive decline (P/CD) in patients treated with valproate (VPA) after 1 year of treatment and at least 1 year of follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three hundred sixty-four patients with various epileptic syndromes and seizure types were treated with VPA mono- or polytherapy for more than 1 year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found five cases of P/CD (1.37%; 95% CI, 0.18-2.56%). Among 140 patients with different adverse effects (AEs) of VPA, P/CD were among the rarest in frequency but significant in terms of drug discontinuation (five of 17).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early identification of this type of AE and discontinuation of the drug led to complete recovery in affected patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ristić</LastName><ForeName>Aleksandar J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vojvodić</LastName><ForeName>Nikola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Janković</LastName><ForeName>Slavko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sindelić</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sokić</LastName><ForeName>Dragoslav</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004827">Epilepsy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014635">Valproic Acid</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">EPI711</ArticleId><ArticleId IdType="doi">10.1111/j.1528-1167.2006.00711.x</ArticleId><ArticleId IdType="pubmed">17201721</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17201721
|texte= The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17201721" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |